Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ajmg.c.30282 http://scihub22266oqcxt.onion/10.1002/ajmg.c.30282 20981776/?report=reader!3022344!20981776     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20981776&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Med+Genet+C+Semin+Med+Genet 2010 ; 154C (4): 463-8 Nephropedia Template TP {{tp|p=20981776|t=2010. Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome |pdf=|usr=}}{{20981776}} gab.com Text Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome JO: Am J Med Genet C Semin Med Genet http://www.kidney.de/pget.php?&tw=1&pmid=20981776 #FOAvip Smith-Magenis syndrome (SMS) is a complex genetic syndrome caused by an interstitial deletion of chromosome 17p11.2. Children and adults with SMS appear to have unique neurobehavioral problems that include: sleep disturbance, self-injurious and maladaptive behaviors, stereotypies, and sensory integration disorders. We gathered retrospective psychotropic use information from parents or other caregivers of 62 individuals with SMS who were asked about use of psychotropic medication from a list of commonly used psychiatric medications. For those drugs identified, respondents were asked to rate the experience with the particular medication using a likert-type scale. Drugs were grouped into seven main categories: (1) stimulants; (2) antidepressants; (3) antipsychotics; (4) sleep aides; (5) mood stabilizers; (6) alpha 2 agonists; and (7) benzodiazepines. Relative frequencies, means and standard deviations pertaining to age and medication effect were derived for each medication category. Six of the seven medication categories examined showed no meaningful deviations from the "no change" score. The benzodiazepine group showed a mild detrimental effect. There were no gender differences in efficacy. Use of psychotropic medication started early in life (mean age 5 years), particularly with sleep aides. Although no medication category was identified as efficacious in SMS, all the categories reported herein may be considered as an option for brief symptomatic relief. Twit Text FOAVip Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome ????Am J Med Genet C Semin Med Genet http://www.kidney.de/pget.php?&tw=1&pmid=20981776 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=20981776 #FOAvip English Wikipedia <ref>{{Cite pmid|20981776}}</ref> Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome #MMPMID20981776 Laje G; Bernert R; Morse R; Pao M; Smith AC Am J Med Genet C Semin Med Genet 2010[Nov]; 154C (4): 463-8 PMID20981776show ga Smith-Magenis syndrome (SMS) is a complex genetic syndrome caused by an interstitial deletion of chromosome 17p11.2. Children and adults with SMS appear to have unique neurobehavioral problems that include: sleep disturbance, self-injurious and maladaptive behaviors, stereotypies, and sensory integration disorders. We gathered retrospective psychotropic use information from parents or other caregivers of 62 individuals with SMS who were asked about use of psychotropic medication from a list of commonly used psychiatric medications. For those drugs identified, respondents were asked to rate the experience with the particular medication using a likert-type scale. Drugs were grouped into seven main categories: (1) stimulants; (2) antidepressants; (3) antipsychotics; (4) sleep aides; (5) mood stabilizers; (6) alpha 2 agonists; and (7) benzodiazepines. Relative frequencies, means and standard deviations pertaining to age and medication effect were derived for each medication category. Six of the seven medication categories examined showed no meaningful deviations from the "no change" score. The benzodiazepine group showed a mild detrimental effect. There were no gender differences in efficacy. Use of psychotropic medication started early in life (mean age 5 years), particularly with sleep aides. Although no medication category was identified as efficacious in SMS, all the categories reported herein may be considered as an option for brief symptomatic relief. |Adult[MESH] |Age Factors[MESH] |Analysis of Variance[MESH] |Attention Deficit and Disruptive Behavior Disorders/*drug therapy/*physiopathology[MESH] |Child[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Psychotropic Drugs/classification/*therapeutic use[MESH] |Retrospective Studies[MESH] |Smith-Magenis Syndrome/*physiopathology[MESH] |Surveys and Questionnaires[MESH]Pharmacological treatment of disruptive behavior in Smith-Magenis synd(epmc).pdf DeepDyve Pubget Overpricing